Cell line · CVCL_4973
Papers18
1 to 18 of 18
Download this page as JSON| Paper | Journal | Year | How we know | Retracted | Source |
|---|---|---|---|---|---|
| An SLCO2B1 mRNA Isoform Acts as a Noncoding RNA to Drive Cancer Progression by Triggering Protein Biosynthesis. | Cancer Res | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Impaired nitrogenous waste clearance promotes hepatocellular carcinoma. | Sci Adv | 2026 | Its Methods give the RRID and name the line | PubMed | |
| CRISPR screening reveals that RNA helicase DDX41 triggers ribosome biogenesis and cancer progression through R-loop-mediated RPL/RPS transcription. | Nat Commun | 2025 | Its Methods give the RRID and name the line | PubMed | |
| VPS45 Contributes to the Progression of Hepatocellular Carcinoma by Triggering the Wnt/β-Catenin Signaling Pathway. | Mol Carcinog | 2025 | Its Methods give the RRID and name the line | PubMed | |
| HBV Remodels PP2A Complexes to Rewire Kinase Signaling in Hepatocellular Carcinoma. | Cancer Res | 2025 | Its Methods give the RRID and name the line | PubMed | |
| SIGLEC15, negatively correlated with PD-L1 in HCC, could induce CD8+ T cell apoptosis to promote immune evasion. | Oncoimmunology | 2024 | Its Methods give the RRID and name the line | PubMed | |
| Macrophage-coated tumor cluster aggravates hepatoma invasion and immunotherapy resistance via generating local immune deprivation. | Cell Rep Med | 2024 | Its Methods give the RRID and name the line | PubMed | |
| CD58 acts as a tumor promotor in hepatocellular carcinoma via activating the AKT/GSK-3β/β-catenin pathway. | J Transl Med | 2023 | Its Methods give the RRID and name the line | PubMed | |
| Single-cell multiomics reveals heterogeneous cell states linked to metastatic potential in liver cancer cell lines. | iScience | 2022 | Its Methods give the RRID and name the line | PubMed | |
| GNA14's interaction with RACK1 inhibits hepatocellular carcinoma progression through reducing MAPK/JNK and PI3K/AKT signaling pathway. | Carcinogenesis | 2021 | Its Methods give the RRID and name the line | PubMed | |
| ATE1 Inhibits Liver Cancer Progression through RGS5-Mediated Suppression of Wnt/β-Catenin Signaling. | Mol Cancer Res | 2021 | Its Methods give the RRID and name the line | PubMed | |
| Increased dopamine and its receptor dopamine receptor D1 promote tumor growth in human hepatocellular carcinoma. | Cancer Commun (Lond) | 2020 | Its Methods give the RRID and name the line | PubMed | |
| Study on the hepatocellular carcinoma model with metastasis. | Genes Dis | 2020 | Cellosaurus cites it | PubMed | |
| Oxaliplatin resistance is enhanced by saracatinib via upregulation Wnt-ABCG1 signaling in hepatocellular carcinoma. | BMC Cancer | 2020 | Its Methods give the RRID and name the line | PubMed | |
| Genomic landscape of copy number aberrations enables the identification of oncogenic drivers in hepatocellular carcinoma. | Hepatology | 2013 | Cellosaurus cites it | PubMed | |
| Stepwise metastatic human hepatocellular carcinoma cell model system with multiple metastatic potentials established through consecutive in vivo selection and studies on metastatic characteristics. | J Cancer Res Clin Oncol | 2004 | Cellosaurus cites it | PubMed | |
| Proteome analysis of hepatocellular carcinoma cell strains, MHCC97-H and MHCC97-L, with different metastasis potentials. | Proteomics | 2004 | Cellosaurus cites it | PubMed | |
| Establishment of cell clones with different metastatic potential from the metastatic hepatocellular carcinoma cell line MHCC97. | World J Gastroenterol | 2001 | Cellosaurus cites it | PubMed |
cell-lines-2026-11-14-0.1.0
Sources 4
- CellosaurusCC BY 4.0, with credit to Cellosaurus (SIB)
- PubMed Central's articlesTitles shown only for CC0, CC BY and public domain articles
- NLM's PMC Article DatasetsCourtesy of NLM, which does not endorse this database
- PubMedNLM's terms
Each source's terms
- CellosaurusCC BY 4.0. Cellosaurus's README: "we have chosen to apply the Creative Commons Attribution 4.0 International (CC BY 4.0) license to Cellosaurus (https://creativecommons.org/licenses/by/4.0/). This means that you are free to copy and redistribute Cellosaurus in any medium or format. You can remix, transform, and build upon Cellosaurus for any purpose, even commercially. You must give appropriate credit, provide a link to the license, and indicate if changes were made." Copyright (c) CALIPHO group, SIB Swiss Institute of Bioinformatics. Read on 14 Nov 2026 at https://ftp.expasy.org/databases/cellosaurus/README
- PubMed Central's articlesEach article's own license. Its words show only under CC0, CC BY or public domain
- NLM's PMC Article DatasetsNLM's PMC Article Datasets on AWS, https://registry.opendata.aws/ncbi-pmc. Its terms: users "acknowledge NLM as the source of the data in a clear and conspicuous manner", do not use the PubMed Central wordmark or the PMC logo, do not "indicate or imply that NLM/NIH/HHS has endorsed" a product, and "only distribute data that are licensed for redistribution". Each article keeps its own license: https://pmc.ncbi.nlm.nih.gov/about/copyright/
- PubMedNLM's terms
Cellosaurus, SIB Swiss Institute of Bioinformatics, https://www.cellosaurus.org, CC BY 4.0. Its problem notes are given in its own words.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/cell-lines/v1/CVCL_4973/papers